|
Ala T. With difficult patients, a less definitive
diagnosis can be helpful. (Guest Editorial). Am J
Alzheimers Dis Other Demen. 2004;19:79-80.
Ala TA, Mattson MD, Frey WH II. The clinical diagnosis
of Alzheimer's disease without the use of head imaging
studies. A cliniconeuropathological study. J Alzheimers
Disease. 2003;5:463-465.
Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble
RJ. The Mini-Mental State exam may help in the differentiation
of dementia with Lewy bodies and Alzheimer's disease.
Research and Practice in Alzheimer's Disease. 2003;7:231-235.
Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble
RJ. The Mini-Mental State exam may help in the differentiation
of dementia with Lewy bodies and Alzheimer's disease.
Int J Geriatr Psychiatry. 2002;17:503-509.
Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble
RJ. Pentagon copying is more impaired in dementia
with Lewy bodies than in Alzheimer's disease. J Neurol
Neurosurg Psychiatry. 2001;70:483-488.
Ala TA, Yang K-H, Sung JH, Frey WH II. Inconsistency
between severe substantia nigra degeneration with
Lewy bodies and clinical parkinsonism in dementia
patients. Acta Neuropathol (Berl). 2000;99:511-516.
Ala TA, Beh GO, Frey WH II. Pure hippocampal sclerosis.
A rare cause of dementia mimicking Alzheimer‚s
disease. Neurology. 2000;54:843-848.
Ala TA, Yang K-H, Sung JH, Frey WH II. Clinical parkinsonism
in dementia patients with substantia nigra Lewy bodies.
J Neural Transm. 1999;106:46-57.
Chen X-Q, Fawcett JR, Rahman Y-E, Ala TA, Frey WH
II. Delivery of nerve growth factor to the brain via
the olfactory pathway. J Alzheimers Disease. 1998;1:35-44.
Kjome JR, Swenson KA, Johnson MN, Bordayo EZ, Anderson
LE, Klevan LC, Fraticelli AI, Aldrich SL, Fawcett
JR, Venters HD Jr, Ala TA, Frey WH II. Inhibition
of antagonist and agonist binding to the human brain
muscarinic receptor by arachidonic acid. J Mol Neurosci.
1998;10:209-218.
Ala TA, Yang K-H, Sung JH, Frey WH II. Hallucinations
and signs of parkinsonism help distinguish patients
with dementia and cortical Lewy bodies from patients
with Alzheimer‚s disease at time of presentation:
a clinicopathologic study. J Neurol Neurosurg Psychiatry.
1997;62:16-21.
Frey WH II, Liu J, Chen X, Thorne RG, Ala TA, Rahman
Y-E. Delivery of 125I-NGF to the brain via the olfactory
route. Drug Delivery. 1997;4:87-92.
Venters HD Jr, Ala TA, Frey WH II. Inhibition of antagonist
binding to the human brain muscarinic receptor by
vanadium compounds. Recep Signal Transduct. 1997;7:137-142.
Venters HD Jr, Bonilla LE, Jensen T, Garner HP, Bordayo
EZ, Najarian MN, Ala TA, Mason RP, Frey WH II. Heme
from Alzheimer‚s brain inhibits muscarinic receptor
binding via thiyl radical generation. Brain Res. 1997;764:93-100.
Frey WH II, Najarian MM, Kumar KS, Emory CR, Menning
PM, Frank JC, Johnson MN, Ala TA. Endogenous Alzheimer‚s
brain factor and oxidized glutathione inhibit antagonist
binding to the muscarinic receptor. Brain Res. 1996;714:87-94.
Ala TA, Frey WH II. Validation of the NINCDS-ADRDA
criteria regarding gait in the clinical diagnosis
of Alzheimer's disease: a clinicopathologic study.
Alzheimer Dis Assoc Disord. 1995;9:152-9.
Thorne RG, Emory CR, Ala TA, Frey WH II. Quantitative
assessment of protein transport to the rat olfactory
bulb following intranasal administration: implications
for drug delivery. Brain Res. 1995;692:278-82.
Ala TA, Perfetti PA, Frey WH II. Two cases of acute
anti-GM1 antibody elevations in response to exogenous
GM1 without neurologic symptoms. J Neuroimmunol. 1994;53:109-13.
|
